Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma Read more
Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release. Read more
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Axicabtagene Ciloleucel Read more
Expanded Access Study for the Treatment of Patients with Commercially Out-of-Specification Brexucabtagene Autoleucel Read more
Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release Read more
Post-Transplant Chimerism Patterns in Patients with Myelodysplastic Syndromes and Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation at the John Theurer Cancer Center Read more
Dynamic Changes in Pre- and Post-Transplant NGS MRD Status For Prediction of the Allogeneic Stem Cell Transplant Outcome in Patients with AML Read more
